Partial
Partially Aligned
Patient Risk:
Low
Summary
One claim (drug identity: amoxicillin/clavulanate) is supported by the provided label excerpts; all other claims are unsupported by the supplied label sections, including the meaning of “625” and all marketing/manufacturer/generic-specific assertions.
Category Scores
Accurate Statements
Augmentin is the brand name for the antibiotic combination amoxicillin/clavulanate.
11 DESCRIPTION: “AUGMENTIN is an oral antibacterial combination consisting of amoxicillin and the beta-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).”
Unsupported Statements
The “625” strength usually means 500 mg amoxicillin plus 125 mg clavulanate per tablet.
The provided label excerpts discuss oral suspension strengths (e.g., 125 mg/31.25 mg per 5 mL and 250 mg/62.5 mg per 5 mL) and do not state any tablet “625” formulation or provide a mapping to 500 mg/125 mg per tablet.
In the United States, Augmentin is marketed/manufactured by Pfizer.
No marketing/manufacturing company information is present in the provided label sections.
In many other countries, Augmentin is handled by GlaxoSmithKline (GSK) or by local licensees.
No international marketing/handling/licensing information is present in the provided label sections.
There are generic versions of Augmentin made by other manufacturers, including Teva, Sandoz, and Mylan.
No information about generic manufacturers is present in the provided label sections.
Contradictions
Important Omissions
No omission flagged for safety/efficacy because the user request/claims evaluated were identity strength/market-manufacturer details only, and no other label sections (e.g., boxed warnings, contraindications, dosing) were provided to compare against.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claim concerns product identity (amoxicillin/clavulanate). The unsupported claims relate to strength interpretation and market/manufacturer details; no supported safety warnings or dosing instructions were provided to confirm accuracy beyond the identity statement.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts (tablet “625” mapping and all marketing/manufacturer/generic-specific assertions).
Suggested Improvement
Limit statements to what is supported by the provided label text, or provide the relevant FDA label sections for tablet strength and manufacturer/marketing information before asserting them.